Jump to content

Evenamide

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Bender the Bot (talk | contribs) at 03:41, 30 October 2016 (→‎top: http→https for Google Books and Google News using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Evenamide
Clinical data
ATC code
  • None
Identifiers
  • 2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H26N2O2
Molar mass278.38984 g/mol g·mol−1
3D model (JSmol)
  • CCCCOC1=CC=CC(=C1)CCNCC(=O)N(C)C
  • InChI=1S/C16H26N2O2/c1-4-5-11-20-15-8-6-7-14(12-15)9-10-17-13-16(19)18(2)3/h6-8,12,17H,4-5,9-11,13H2,1-3H3
  • Key:GRHBODILPPXVKN-UHFFFAOYSA-N

Evenamide (INN) (developmental code names NW-3509, NW-3509A) is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Nav1.3, Nav1.7, and Nav1.8, that is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia.[1][2][3][4] The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression.[3] It has completed phase I clinical trials, and phase II clinical trials will be commenced in the third quarter of 2015.[1]

See also

References

  1. ^ "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595.
  2. ^ Progress in Medicinal Chemistry. Elsevier. 6 October 2010. pp. 81–. ISBN 978-0-12-381293-3.
  3. ^ a b Satya Prakash Gupta (21 June 2011). Ion Channels and Their Inhibitors. Springer Science & Business Media. pp. 102–. ISBN 978-3-642-19922-6.
  4. ^ Zuliani, Valentina; Amori, Laura; Rivara, Mirko (2011). "Advances in Design and Development of Sodium Channel Blockers": 79–115. doi:10.1007/978-3-642-19922-6_4. {{cite journal}}: Cite journal requires |journal= (help)